Moderna Inc.’s stock fell 6.4% Wednesday, after the company said that its respiratory syncytial virus, or RSV, shot showed 50% efficacy in preventing the illness after 18 months.
Source link
Kash Patel, Trump’s pick to be FBI director, targeted in Iranian-backed cyberattack
Kash Patel, Former Chief of Staff to the Defense Secretary speaks on the day Republican presidential nominee and former U.S....